
ImmunityBio in pact to acquire certain assets, leasehold interest from Athenex
8.79BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US45256X1037
CUSIP
45256X103
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
-0.99
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.96
Wall Street Target Price
14.25
EPS Estimate Current Year
-0.92
EPS Estimate Next Year
-0.07
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.07
Most Recent Quarter
-
Revenue TTM
165,792,000
Gross Profit TTM
164,696,992
EBITDA
-235,298,000
Profit Margin
0.00%
Return On Assets TTM
-30.54%
Return On Equity TTM
0.00%
Revenue Per Share TTM
0.165
Qtly Revenue Growth YOY
93.90%
Diluted Eps TTM
-0.96
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
82
Price Sales TTM
50.8209
Price Book MRQ
0
Enterprise Value Revenue
55
Enterprise Value EBITDA
-8
903.08
3.20%227.40
2.97%965.00
0.55%314.92
0.35%900.30
0.00%139.16
0.00%528.21
-4.77%355.10
-2.26%34.64
-2.01%153.70
-1.47%